The DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors
Open accessAbstract
Recent clinical trials have shown that sodium glucose co-transport 2 (SGLT2) inhibitors have dramatic beneficial cardiovascular outcomes. These include a reduced incidence of cardiovascular death and heart failure hospitalization in people with and without diabetes, and those with and without prevalent heart failure. The actual mechanism(s) responsible for these beneficial effects are not completely clear. Several potential theses have been proposed to explain the cardioprotective effects of SGLT2 inhibition, which include diuresis/natriuresis, blood pressure reduction, erythropoiesis, improved cardiac energy metabolism, inflammation reduction, inhibition of the sympathetic nervous system, prevention of adverse cardiac remodeling, prevention of ischemia/reperfusion injury, inhibition of the Na+/H+-exchanger, inhibition of SGLT1, reduction in hyperuricemia, increasing autophagy and lysosomal degradation, decreasing epicardial fat mass, increasing erythropoietin levels, increasing circulating pro-vascular progenitor cells, decreasing oxidative stress, and improving vascular function. The strengths and weaknesses of these proposed mechanisms are reviewed in an effort to try to synthesize and prioritize the mechanisms as they relate to clinical event reduction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citationDapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845
The Failing Heart — An Engine Out of Fuel
Neubauer, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmra063052 · Cited by 2,417
Myocardial Fatty Acid Metabolism in Health and Disease
Lopaschuk, G. D., Ussher, J. R., Folmes, C. D. L., Jaswal, J. S., & Stanley, W. C. (2010) · Physiological Reviews · doi:10.1152/physrev.00015.2009 · Cited by 2,179
Self-citationThe ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease
Youm, Y.-H., Nguyen, K. Y., Grant, R. W., Goldberg, E. L., Bodogai, M., Kim, D., D'Agostino, D., Planavsky, N., Lupfer, C., Kanneganti, T. D., et al. (2015) · Nature Medicine · doi:10.1038/nm.3804 · Cited by 2,172
Endemann, D. H., & Schiffrin, E. L. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000132474.50966.da · Cited by 1,198
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Verma, S., & McMurray, J. J. V. (2018) · Diabetologia · doi:10.1007/s00125-018-4670-7 · Cited by 999
Self-citationCV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
Ferrannini, E., Mark, M., & Mayoux, E. (2016) · Diabetes Care · doi:10.2337/dc16-0330 · Cited by 975
Mitochondrial dysfunction in pathophysiology of heart failure
Zhou, B., & Tian, R. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120849 · Cited by 923
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
Lambers Heerspink, H. J., de Zeeuw, D., Wie, L., Leslie, B., & List, J. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12127 · Cited by 837
The war against heart failure: the Lancet lecture
Braunwald, E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61889-4 · Cited by 811
Ferrannini, E., Baldi, S., Frascerra, S., Astiarraga, B., Heise, T., Bizzotto, R., Mari, A., Pieber, T. R., & Muscelli, E. (2016) · Diabetes · doi:10.2337/db15-1356 · Cited by 712
The Failing Heart Relies on Ketone Bodies as a Fuel
Aubert, G., Martin, O. J., Horton, J. L., Lai, L., Vega, R. B., Leone, T. C., Koves, T., Gardell, S. J., Krüger, M., Hoppel, C. L., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.017355 · Cited by 707
Chronic Heart Failure and Inflammation: What Do We Really Know?
Dick, S. A., & Epelman, S. (2016) · Circulation Research · doi:10.1161/circresaha.116.308030 · Cited by 692
Baartscheer, A., Schumacher, C. A., Wüst, R. C. I., Fiolet, J. W. T., Stienen, G. J. M., Coronel, R., & Zuurbier, C. J. (2017) · Diabetologia · doi:10.1007/s00125-016-4134-x · Cited by 661
Santos-Gallego, C. G., Requena-Ibanez, J. A., San Antonio, R., Ishikawa, K., Watanabe, S., Picatoste, B., Flores, E., Garcia-Ropero, A., Sanz, J., Hajjar, R. J., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.01.056 · Cited by 651
Bedi, K. C., Snyder, N. W., Brandimarto, J., Aziz, M., Mesaros, C., Worth, A. J., Wang, L. L., Javaheri, A., Blair, I. A., Margulies, K. B., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.017545 · Cited by 650
Li, C., Zhang, J., Xue, M., Li, X., Han, F., Liu, X., Xu, L., Lu, Y., Cheng, Y., Li, T., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0816-2 · Cited by 580
Mudaliar, S., Alloju, S., & Henry, R. R. (2016) · Diabetes Care · doi:10.2337/dc16-0542 · Cited by 571
Nielsen, R., Møller, N., Gormsen, L. C., Tolbod, L. P., Hansson, N. H., Sorensen, J., Harms, H. J., Frøkiær, J., Eiskjaer, H., Jespersen, N. R., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.036459 · Cited by 518
Lee, T.-M., Chang, N.-C., & Lin, S.-Z. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.01.035 · Cited by 504
Hallow, K. M., Helmlinger, G., Greasley, P. J., McMurray, J. J. V., & Boulton, D. W. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13126 · Cited by 499
Schernthaner, G., Gross, J. L., Rosenstock, J., Guarisco, M., Fu, M., Yee, J., Kawaguchi, M., Canovatchel, W., & Meininger, G. (2013) · Diabetes Care · doi:10.2337/dc12-2491 · Cited by 480
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s010 · Cited by 471
Heerspink, H. J. L., Perco, P., Mulder, S., Leierer, J., Hansen, M. K., Heinzel, A., & Mayer, G. (2019) · Diabetologia · doi:10.1007/s00125-019-4859-4 · Cited by 457
Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences
Gallo, L. A., Wright, E. M., & Vallon, V. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114561992 · Cited by 395
Chino, Y., Samukawa, Y., Sakai, S., Nakai, Y., Yamaguchi, J., Nakanishi, T., & Tamai, I. (2014) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1909 · Cited by 389
Empagliflozin Increases Cardiac Energy Production in Diabetes
Verma, S., Rawat, S., Ho, K. L., Wagg, C. S., Zhang, L., Teoh, H., Dyck, J. E., Uddin, G. M., Oudit, G. Y., Mayoux, E., et al. (2018) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2018.07.006 · Cited by 386
Self-citationThe effect of dapagliflozin treatment on epicardial adipose tissue volume
Sato, T., Aizawa, Y., Yuasa, S., Kishi, S., Fuse, K., Fujita, S., Ikeda, Y., Kitazawa, H., Takahashi, M., Sato, M., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0658-8 · Cited by 378
Mazer, C. D., Hare, G. M. T., Connelly, P. W., Gilbert, R. E., Shehata, N., Quan, A., Teoh, H., Leiter, L. A., Zinman, B., Jüni, P., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044235 · Cited by 371
Self-citationThe failing heart utilizes 3-hydroxybutyrate as a metabolic stress defense
Horton, J. L., Davidson, M. T., Kurishima, C., Vega, R. B., Powers, J. C., Matsuura, T. R., Petucci, C., Lewandowski, E. D., Crawford, P. A., Muoio, D. M., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.124079 · Cited by 364
Mazidi, M., Rezaie, P., Gao, H., & Kengne, A. P. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.004007 · Cited by 347 · cited 1×
“Because SGLT2 inhibitors lower blood pressure (19), some of the beneficial effects of SGLT2 inhibitors in the setting of heart failure have been suggested to be related to this blood pressure improved cardiac energetics with SGLT2 inhibition lowering effect.”
BackgroundEmerging role of SGLT-2 inhibitors for the treatment of obesity
Pereira, M. J., & Eriksson, J. W. (2019) · Drugs · doi:10.1007/s40265-019-1057-0 · Cited by 342
Tahara, A., Kurosaki, E., Yokono, M., Yamajuku, D., Kihara, R., Hayashizaki, Y., Takasu, T., Imamura, M., Li, Q., Tomiyama, H., et al. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.05.014 · Cited by 310
Shao, Q., Meng, L., Lee, S., Tse, G., Gong, M., Zhang, Z., Zhao, J., Zhao, Y., Li, G., & Liu, T. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0964-4 · Cited by 293
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
(2019) · New England Journal of Medicine · doi:10.1056/nejmc1902837 · Cited by 290
Zhang, L., Jaswal, J. S., Ussher, J. R., Sankaralingam, S., Wagg, C., Zaugg, M., & Lopaschuk, G. D. (2013) · Circulation: Heart Failure · doi:10.1161/circheartfailure.112.000228 · Cited by 269
Self-citationMentzer, R. M., Bartels, C., Bolli, R., Boyce, S., Buckberg, G. D., Chaitman, B., Haverich, A., Knight, J., Menasché, P., Myers, M. L., et al. (2008) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2007.10.054 · Cited by 264
Byrne, N. J., Matsumura, N., Maayah, Z. H., Ferdaoussi, M., Takahara, S., Darwesh, A. M., Levasseur, J. L., Jahng, J. W. S., Vos, D., Parajuli, N., et al. (2020) · Circulation: Heart Failure · doi:10.1161/circheartfailure.119.006277 · Cited by 257
Self-citationWeber, M. A., Mansfield, T. A., Cain, V. A., Iqbal, N., Parikh, S., & Ptaszynska, A. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00417-9 · Cited by 254
Sano, M., Takei, M., Shiraishi, Y., & Suzuki, Y. (2016) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2760w · Cited by 252
The Role of Autophagy in Vascular Biology
Nussenzweig, S. C., Verma, S., & Finkel, T. (2015) · Circulation Research · doi:10.1161/circresaha.116.303805 · Cited by 244
Self-citationMancini, S. J., Boyd, D., Katwan, O. J., Strembitska, A., Almabrouk, T. A., Kennedy, S., Palmer, T. M., & Salt, I. P. (2018) · Scientific Reports · doi:10.1038/s41598-018-23420-4 · Cited by 240
Verma, S., Garg, A., Yan, A. T., Gupta, A. K., Al-Omran, M., Sabongui, A., Teoh, H., Mazer, C. D., & Connelly, K. A. (2016) · Diabetes Care · doi:10.2337/dc16-1312 · Cited by 232
Self-citationRole of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2
Matthews, V. B., Elliot, R. H., Rudnicka, C., Hricova, J., Herat, L., & Schlaich, M. P. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001434 · Cited by 222
(2019) · Cellular Physiology and Biochemistry · doi:10.33594/000000178 · Cited by 211
Lee, H.-C., Shiou, Y.-L., Jhuo, S.-J., Chang, C.-Y., Liu, P.-L., Jhuang, W.-J., Dai, Z.-K., Chen, W.-Y., Chen, Y.-F., & Lee, A.-S. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0849-6 · Cited by 204
Juni, R. P., Kuster, D. W. D., Goebel, M., Helmes, M., Musters, R. J. P., van der Velden, J., Koolwijk, P., Paulus, W. J., & van Hinsbergh, V. W. M. (2019) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2019.04.003 · Cited by 202
Ho, K. L., Zhang, L., Wagg, C., Al Batran, R., Gopal, K., Levasseur, J., Leone, T., Dyck, J. R. B., Ussher, J. R., Muoio, D. M., et al. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz045 · Cited by 196
Self-citationLee, P. C., Ganguly, S., & Goh, S. ‐. (2018) · Obesity Reviews · doi:10.1111/obr.12755 · Cited by 189
A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity
Sano, M. (2018) · Journal of Cardiology · doi:10.1016/j.jjcc.2017.12.004 · Cited by 188
Uthman, L., Baartscheer, A., Schumacher, C. A., Fiolet, J. W. T., Kuschma, M. C., Hollmann, M. W., Coronel, R., Weber, N. C., & Zuurbier, C. J. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01575 · Cited by 188
SGLT‐2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects
Lam, C. S. P., Chandramouli, C., Ahooja, V., & Verma, S. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.013389 · Cited by 183
Self-citationCai, X., Yang, W., Gao, X., Chen, Y., Zhou, L., Zhang, S., Han, X., & Ji, L. (2018) · Obesity · doi:10.1002/oby.22066 · Cited by 181 · cited 1×
“Clinical studies have consistently shown body weight reduction in patients treated with SGLT2 inhibitors (62).”
BackgroundFerrannini, E., Baldi, S., Frascerra, S., Astiarraga, B., Barsotti, E., Clerico, A., & Muscelli, E. (2017) · Diabetes Care · doi:10.2337/dc16-2724 · Cited by 181
Briasoulis, A., Androulakis, E., Christophides, T., & Tousoulis, D. (2016) · Heart Failure Reviews · doi:10.1007/s10741-016-9533-z · Cited by 174
Leng, W., Ouyang, X., Lei, X., Wu, M., Chen, L., Wu, Q., Deng, W., & Liang, Z. (2016) · Mediators of Inflammation · doi:10.1155/2016/6305735 · Cited by 172
Byrne, N. J., Parajuli, N., Levasseur, J. L., Boisvenue, J., Beker, D. L., Masson, G., Fedak, P. W. M., Verma, S., & Dyck, J. R. B. (2017) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2017.07.003 · Cited by 171
Self-citationMori, J., Basu, R., McLean, B. A., Das, S. K., Zhang, L., Patel, V. B., Wagg, C. S., Kassiri, Z., Lopaschuk, G. D., & Oudit, G. Y. (2012) · Circulation: Heart Failure · doi:10.1161/circheartfailure.112.966705 · Cited by 170
Self-citationIannantuoni, F., M. de Marañon, A., Diaz-Morales, N., Falcon, R., Bañuls, C., Abad-Jimenez, Z., Victor, V. M., Hernandez-Mijares, A., & Rovira-Llopis, S. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8111814 · Cited by 166
Kang, S., Verma, S., Hassanabad, A. F., Teng, G., Belke, D. D., Dundas, J. A., Guzzardi, D. G., Svystonyuk, D. A., Pattar, S. S., Park, D. S. J., et al. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2019.08.033 · Cited by 166
Self-citationHare, J. M., & Johnson, R. J. (2003) · Circulation · doi:10.1161/01.cir.0000066420.36123.35 · Cited by 164
Revisiting the links between glycaemia, diabetes and cardiovascular disease
Sattar, N. (2013) · Diabetologia · doi:10.1007/s00125-012-2817-5 · Cited by 163 · cited 2×
“Hyperglycemia itself has been shown to be a weak risk factor for cardiovascular disease (65).”
BackgroundLim, V. G., Bell, R. M., Arjun, S., Kolatsi-Joannou, M., Long, D. A., & Yellon, D. M. (2019) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2018.10.002 · Cited by 162
The Importance of NLRP3 Inflammasome in Heart Failure
Butts, B., GARY, R. A., Dunbar, S. B., & Butler, J. (2015) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2015.04.014 · Cited by 147
Gaspari, T. A., Spizzo, I., Liu, H., Hu, Y., Simpson, R. W., Widdop, R. E., & Dear, A. E. (2017) · Diabetes and Vascular Disease Research · doi:10.1177/1479164117733626 · Cited by 142
Empagliflozin’s Fuel Hypothesis: Not so Soon
Lopaschuk, G. D., & Verma, S. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.07.018 · Cited by 134
Self-citationConnelly, K. A., Zhang, Y., Visram, A., Advani, A., Batchu, S. N., Desjardins, J., Thai, K., & Gilbert, R. E. (2019) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2018.11.010 · Cited by 126
Cannon, C. P., Perkovic, V., Agarwal, R., Baldassarre, J., Bakris, G., Charytan, D. M., de Zeeuw, D., Edwards, R., Greene, T., Heerspink, H. J. L., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044359 · Cited by 117
Dapagliflozin Attenuates Na+/H+ Exchanger-1 in Cardiofibroblasts via AMPK Activation
Ye, Y., Jia, X., Bajaj, M., & Birnbaum, Y. (2018) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-018-6837-3 · Cited by 115
Hess, D. A., Terenzi, D. C., Trac, J. Z., Quan, A., Mason, T., Al-Omran, M. A., Bhatt, D. L., Dhingra, N., Rotstein, O. D., Leiter, L. A., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.08.015 · Cited by 115
Self-citationRaggi, P., Gadiyaram, V., Zhang, C., Chen, Z., Lopaschuk, G., & Stillman, A. E. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.013104 · Cited by 113
Self-citationSGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses
Filippatos, T. D., Liontos, A., Papakitsou, I., & Elisaf, M. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1581971 · Cited by 110
Packer, M. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13229 · Cited by 108
ESTERLINE, R. L., Vaag, A. A., Oscarsson, J., & Vora, J. P. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0832 · Cited by 106
Egea, O. I., Santiago‐Vacas, E., Yurista, S. R., Lupón, J., Packer, M., Heymans, S. R. B., Zannad, F. M., Butler, J., Pascual-Figal, D. A., Lax, A., et al. (2019) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2019.07.010 · Cited by 105
Hypovolemia and neurovascular control during orthostatic stress
Kimmerly, D. S., & Shoemaker, J. K. (2002) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00535.2001 · Cited by 102
Empagliflozin Protects against Diet-Induced NLRP-3 Inflammasome Activation and Lipid Accumulation
Benetti, E., Mastrocola, R., Vitarelli, G., Cutrìn, J. C., Nigro, D., Chiazza, F., Mayoux, E., Collino, M., & Fantozzi, R. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.235069 · Cited by 102
Jordan, J., Tank, J., Heusser, K., Heise, T., Wanner, C., Heer, M., Macha, S., Mattheus, M., Lund, S. S., Woerle, H. J., et al. (2017) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2017.07.005 · Cited by 102
The anti-diabetic drug dapagliflozin induces vasodilation via activation of PKG and Kv channels
Li, H., Shin, S. E., Seo, M. S., An, J. R., Choi, I., Jung, W., Firth, A. L., Lee, D.-S., Yim, M., Choi, G., et al. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.01.032 · Cited by 99
Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms
Staels, B. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.04.009 · Cited by 98
Swoboda, P., McDiarmid, A. K., Erhayiem, B., Ripley, D. P., Dobson, L. E., Garg, P., Musa, T. A., Witte, K. K., Kearney, M. T., Barth, J. H., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.005539 · Cited by 96
Dapagliflozin Attenuates Cardiac Remodeling in Mice Model of Cardiac Pressure Overload
Shi, L. S., Zhu, D., Wang, S., Jiang, A., & Li, F. (2019) · American Journal of Hypertension · doi:10.1093/ajh/hpz016 · Cited by 88
Leng, W., Wu, M., Pan, H., Lei, X., Chen, L., Wu, Q., Ouyang, X., & Liang, Z. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.09.03 · Cited by 80
Jobori, H. A., Daniele, G., Adams, J. M., Cersósimo, E., Triplitt, C. L., DeFronzo, R. A., & Abdul‐Ghani, M. A. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12881 · Cited by 79
Pump, pipes, and filter: do SGLT2 inhibitors cover it all?
Verma, S., Jüni, P., & Mazer, C. D. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32824-1 · Cited by 77
Self-citationSenescent T Cells Predict the Development of Hyperglycemia in Humans
Lee, Y., Kim, S. R., Han, D. H., Yu, H. T., Han, Y. D., Kim, J. H., Kim, S. H., Lee, C. J., Min, B., Kim, D.-H., et al. (2018) · Diabetes · doi:10.2337/db17-1218 · Cited by 75
Myocardial Energetics in Heart Failure With Preserved Ejection Fraction
AbouEzzeddine, O. F., Kemp, B. J., Borlaug, B. A., Mullan, B. P., Behfar, A., Pislaru, S. V., Fudim, M., Redfield, M. M., & Chareonthaitawee, P. (2019) · Circulation Heart Failure · doi:10.1161/circheartfailure.119.006240 · Cited by 73
Chiba, Y., Yamada, T., Tsukita, S., Takahashi, K., Munakata, Y., Shirai, Y., Kodama, S., Asai, Y., Sugisawa, T., Uno, K., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0150756 · Cited by 71
SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection
Bell, R. M., & Yellon, D. M. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30314-5 · Cited by 66
Malonyl CoA Decarboxylase Inhibition Improves Cardiac Function Post-Myocardial Infarction
Wang, W., Zhang, L., Battiprolu, P. K., Fukushima, A., Nguyen, K., Milner, K., Gupta, A. K., Altamimi, T., Byrne, N. J., Mori, J., et al. (2019) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2019.02.003 · Cited by 65
Self-citationCardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms
Staels, B. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.05.013 · Cited by 59
Patel, A. R., Kuvin, J. T., Pandian, N. G., Smith, J. J., Udelson, J. E., Mendelsohn, M. E., Konstam, M. A., & Karas, R. H. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)01057-3 · Cited by 58
The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure
Bhatt, D. L., Verma, S., & Braunwald, E. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.10.008 · Cited by 58
Self-citationButler, J., Handelsman, Y., Bakris, G. L., & Verma, S. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1708 · Cited by 57
Self-citationKario, K., Böhm, M., Mahfoud, F., Townsend, R. R., Weber, M. A., Patel, M. R., Tyson, C. C., Weil, J., Agdirlioglu, T., Cohen, S. A., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.035588 · Cited by 54
Connelly, K. A., Zhang, Y., Desjardins, J., Thai, K., & Gilbert, R. E. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0741-9 · Cited by 50
Management of Comorbid Diabetes Mellitus and Worsening Heart Failure
Khan, S. S., Butler, J., & Gheorghiade, M. (2014) · JAMA · doi:10.1001/jama.2014.4115 · Cited by 49
Yoshikawa, T., Kishi, T., Shinohara, K., Takesue, K., Shibata, R., Sonoda, N., Inoguchi, T., Sunagawa, K., Tsutsui, H., & Hirooka, Y. (2017) · Hypertension Research · doi:10.1038/hr.2017.14 · Cited by 49
Minireview: are SGLT2 inhibitors heart savers in diabetes?
Rotkvić, P. G., Berković, M. C., Bulj, N., & Rotkvić, L. (2019) · Heart Failure Reviews · doi:10.1007/s10741-019-09849-3 · Cited by 28
Lim, V. G., Bell, R., Arjun, S., Kolatsi‐Joannou, M., Long, D. A., & Yellon, D. M. (2018) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2018.05.087 · Cited by 26
Cannon, C. P., Perkovic, V., Agarwal, R., Baldassarre, J. S., Bakris, G. L., Charytan, D. M., de Zeeuw, D., Edwards, R., Greene, T., Heerspink, H., et al. (2019) · UCL Discovery (University College London) · Cited by 12
Cited by
2024 ESC Guidelines for the management of chronic coronary syndromes
Vrints, C., Andreotti, F., Koskinas, K. C., Rossello, X., Adamo, M., Ainslie, J., Banning, A. P., Budaj, A., Buechel, R. R., Chiariello, G. A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae177 · Cited by 2,774
Cardiac Energy Metabolism in Heart Failure
Lopaschuk, G. D., Karwi, Q. G., Tian, R., Wende, A. R., & Abel, E. D. (2021) · Circulation Research · doi:10.1161/circresaha.121.318241 · Cited by 1,373
Self-citationAntar, S. A., Ashour, N. A., Sharaky, M., Khattab, M., Ashour, N. A., Zaid, R. T., Roh, E. J., Elkamhawy, A., & Al-Karmalawy, A. A. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115734 · Cited by 622
Santos-Gallego, C. G., Vargas-Delgado, A. P., Requena-Ibanez, J. A., Garcia-Ropero, A., Mancini, D., Pinney, S., Macaluso, F., Sartori, S., Roque, M., Sabatel-Perez, F., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.008 · Cited by 531
Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function
Vallon, V., & Verma, S. (2021) · Annual Review of Physiology · doi:10.1146/annurev-physiol-031620-095920 · Cited by 516
Self-citation
Metadata
- Authors
- Lopaschuk, G. D., & Verma, S.
- Venue
- JACC: Basic to Translational Science
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 5
- Issue
- 6
- Pages
- 632-644
- ISSN
- 2452-302X (ISSN-L)
- OpenAlex
- W3036816724
- Cited by
- 894
- References
- 107
- FWCI
- 68.15
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.